secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001140361-23-047683
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences completes acquisition of Zynerba for $60M cash plus up to $140M in CVRs
--------------------------------------------------------------------------------

- Purchase price of $1.1059 per share in cash (approx. $60M aggregate) plus one CVR per share worth up to $2.5444.
- Tender offer received 52.3% of Zynerba shares; merger completed on Oct 10, 2023; Zynerba now wholly owned subsidiary.
- Lead candidate Zygel is a synthetic cannabidiol gel in Phase 3 for Fragile X syndrome; also studied in 22q deletion syndrome.
- Zygel granted FDA Fast Track for FXS and orphan designation in US and EU; potential to address ~160,000 US patients.
- Zynerba common stock to be delisted from Nasdaq; Harmony diversifies pipeline beyond sleep/wake therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/0001140361-23-047683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000114036123047683/ny20012277x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-047683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer